LivingGLP1
parallel randomized trial

GALLOP2

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

Other conditionsNCT06788626S000901

Design

Randomized
390
Start year
2025
Treatment
1 weeks, follow-up 12.86 weeks
Countries
China (19 sites)
Sponsor
Wei Hu (not reported)
Eligibility
acute ischemic large vessel occlusion within 24 hours, thrombectomy, no intravenous thrombolysis

Conduct and analysis

Blinding
open label
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Semaglutide 0.5 mg subcutaneous once weekly
Semaglutide 0.5 mg plus thrombectomy
endovascular thrombectomy and guideline antithrombotic care; lifestyle: not reported195
A2Standard care or no added treatment
Thrombectomy alone
endovascular thrombectomy and guideline antithrombotic care; lifestyle: not reported195